secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2022-07-21T23:59:59+00:00
Accession:  0001628280-22-019249
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023
--------------------------------------------------------------------------------

- Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.
- FY2022 gross margin improved to 52% (from 48%); adjusted EBITDA $3.1M vs $2.1M.
- Operating income $607K for FY2022; cash $9.0M, no debt.
- Guidance: projects another year of top-line growth of ~20% for FY2023.
- CEO notes expanding ex-vivo services and computational discovery tools moving to preclinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/0001628280-22-019249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828022019249/csbr8-k4302022.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-019249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer